share_log

SciSparc | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

SciSparc | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

SciSparc | 20-F/A：年度報告/過渡報告/註冊聲明(修正)
美股SEC公告 ·  2024/05/02 21:23

Moomoo AI 已提取核心信息

SciSparc Ltd., a pharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company, which specializes in the development of cannabinoid-based therapeutics, did not generate revenue from its drug development segment but reported revenues of $2,879,000 from online sales of hemp-based products. The cost of goods sold amounted to $683,000, resulting in a gross profit of $2,196,000. Research and development expenses totaled $1,641,000, while general and administrative expenses reached $5,031,000. The company also recorded an impairment of intangible assets amounting to $1,042,000. SciSparc experienced a net loss of $5,883,000 for the year, with a basic and diluted loss per share of $14.43. The company's share of losses from equity-accounted investments was $210,000. Finance income, primarily from changes in the fair value of financial liabilities, was $2,219,000, and finance expenses, including losses from the remeasurement of investments in financial assets, were $1,055,000. The company's future plans include continuing its drug development efforts and expanding its online sales of hemp-based products.
SciSparc Ltd., a pharmaceutical company, reported its annual financial performance for the fiscal year ended December 31, 2023. The company, which specializes in the development of cannabinoid-based therapeutics, did not generate revenue from its drug development segment but reported revenues of $2,879,000 from online sales of hemp-based products. The cost of goods sold amounted to $683,000, resulting in a gross profit of $2,196,000. Research and development expenses totaled $1,641,000, while general and administrative expenses reached $5,031,000. The company also recorded an impairment of intangible assets amounting to $1,042,000. SciSparc experienced a net loss of $5,883,000 for the year, with a basic and diluted loss per share of $14.43. The company's share of losses from equity-accounted investments was $210,000. Finance income, primarily from changes in the fair value of financial liabilities, was $2,219,000, and finance expenses, including losses from the remeasurement of investments in financial assets, were $1,055,000. The company's future plans include continuing its drug development efforts and expanding its online sales of hemp-based products.
制药公司ScisPARC Ltd. 报告了截至2023年12月31日的财年的年度财务业绩。该公司专门开发基于大麻素的疗法，其药物开发部门没有创造收入，但报告称，大麻类产品的在线销售收入为2879,000美元。商品销售成本为68.3万美元，毛利为219.6万美元。研发费用总额为1,641,000美元，而一般和管理费用达到5,031,000美元。该公司还记录了总额为1,042,000美元的无形资产减值。ScisPARC全年净亏损58.3万美元，基本和摊薄后的每股亏损为14.43美元。该公司的股票入账投资亏损份额为21万美元。主要来自金融负债公允价值变动的财务收入为2,219,000美元，包括金融资产投资调整损失在内的财务支出为1,055,000美元。该公司的未来计划包括继续开展药物开发工作和扩大大麻类产品的在线销售。
制药公司ScisPARC Ltd. 报告了截至2023年12月31日的财年的年度财务业绩。该公司专门开发基于大麻素的疗法，其药物开发部门没有创造收入，但报告称，大麻类产品的在线销售收入为2879,000美元。商品销售成本为68.3万美元，毛利为219.6万美元。研发费用总额为1,641,000美元，而一般和管理费用达到5,031,000美元。该公司还记录了总额为1,042,000美元的无形资产减值。ScisPARC全年净亏损58.3万美元，基本和摊薄后的每股亏损为14.43美元。该公司的股票入账投资亏损份额为21万美元。主要来自金融负债公允价值变动的财务收入为2,219,000美元，包括金融资产投资调整损失在内的财务支出为1,055,000美元。该公司的未来计划包括继续开展药物开发工作和扩大大麻类产品的在线销售。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日